7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Adaptation to the cervical environment is associated with increased antibiotic susceptibility in Neisseria gonorrhoeae

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Neisseria gonorrhoeae is an urgent public health threat due to rapidly increasing incidence and antibiotic resistance. In contrast with the trend of increasing resistance, clinical isolates that have reverted to susceptibility regularly appear, prompting questions about which pressures compete with antibiotics to shape gonococcal evolution. Here, we used genome-wide association to identify loss-of-function (LOF) mutations in the efflux pump mtrCDE operon as a mechanism of increased antibiotic susceptibility and demonstrate that these mutations are overrepresented in cervical relative to urethral isolates. This enrichment holds true for LOF mutations in another efflux pump, farAB, and in urogenitally-adapted versus typical N. meningitidis, providing evidence for a model in which expression of these pumps in the female urogenital tract incurs a fitness cost for pathogenic Neisseria. Overall, our findings highlight the impact of integrating microbial population genomics with host metadata and demonstrate how host environmental pressures can lead to increased antibiotic susceptibility.

          Abstract

          Antibiotic resistance in Neisseria gonorrhoeae is rising, yet sometimes strains emerge that have reverted to susceptibility. Here, the authors find that selective pressures from the host may influence susceptibility through loss-of-function mutations in genes that encode for efflux pumps.

          Related collections

          Most cited references67

          • Record: found
          • Abstract: found
          • Article: not found

          Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

          Neisseria gonorrhoeae is evolving into a superbug with resistance to previously and currently recommended antimicrobials for treatment of gonorrhea, which is a major public health concern globally. Given the global nature of gonorrhea, the high rate of usage of antimicrobials, suboptimal control and monitoring of antimicrobial resistance (AMR) and treatment failures, slow update of treatment guidelines in most geographical settings, and the extraordinary capacity of the gonococci to develop and retain AMR, it is likely that the global problem of gonococcal AMR will worsen in the foreseeable future and that the severe complications of gonorrhea will emerge as a silent epidemic. By understanding the evolution, emergence, and spread of AMR in N. gonorrhoeae, including its molecular and phenotypic mechanisms, resistance to antimicrobials used clinically can be anticipated, future methods for genetic testing for AMR might permit region-specific and tailor-made antimicrobial therapy, and the design of novel antimicrobials to circumvent the resistance problems can be undertaken more rationally. This review focuses on the history and evolution of gonorrhea treatment regimens and emerging resistance to them, on genetic and phenotypic determinants of gonococcal resistance to previously and currently recommended antimicrobials, including biological costs or benefits; and on crucial actions and future advances necessary to detect and treat resistant gonococcal strains and, ultimately, retain gonorrhea as a treatable infection. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

            Meningococcus, an obligate human bacterial pathogen, remains a worldwide and devastating cause of epidemic meningitis and sepsis. However, advances have been made in our understanding of meningococcal biology and pathogenesis, global epidemiology, transmission and carriage, host susceptibility, pathophysiology, and clinical presentations. Approaches to diagnosis, treatment, and chemoprophylaxis are now in use on the basis of these advances. Importantly, the next generation of meningococcal conjugate vaccines for serogroups A, C, Y, W-135, and broadly effective serogroup B vaccines are on the horizon, which could eliminate the organism as a major threat to human health in industrialised countries in the next decade. The crucial challenge will be effective introduction of new meningococcal vaccines into developing countries, especially in sub-Saharan Africa, where they are urgently needed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa

              Increasing prevalence and severity of multi-drug-resistant (MDR) bacterial infections has necessitated novel antibacterial strategies. Ideally, new approaches would target bacterial pathogens while exerting selection for reduced pathogenesis when these bacteria inevitably evolve resistance to therapeutic intervention. As an example of such a management strategy, we isolated a lytic bacteriophage, OMKO1, (family Myoviridae) of Pseudomonas aeruginosa that utilizes the outer membrane porin M (OprM) of the multidrug efflux systems MexAB and MexXY as a receptor-binding site. Results show that phage selection produces an evolutionary trade-off in MDR P. aeruginosa, whereby the evolution of bacterial resistance to phage attack changes the efflux pump mechanism, causing increased sensitivity to drugs from several antibiotic classes. Although modern phage therapy is still in its infancy, we conclude that phages, such as OMKO1, represent a new approach to phage therapy where bacteriophages exert selection for MDR bacteria to become increasingly sensitive to traditional antibiotics. This approach, using phages as targeted antibacterials, could extend the lifetime of our current antibiotics and potentially reduce the incidence of antibiotic resistant infections.
                Bookmark

                Author and article information

                Contributors
                ygrad@hsph.harvard.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                17 August 2020
                17 August 2020
                2020
                : 11
                : 4126
                Affiliations
                [1 ]GRID grid.38142.3c, ISNI 000000041936754X, Department of Immunology and Infectious Diseases, , Harvard T.H. Chan School of Public Health, ; Boston, MA USA
                [2 ]GRID grid.10306.34, ISNI 0000 0004 0606 5382, Centre for Genomic Pathogen Surveillance, Wellcome Sanger Institute, , Wellcome Genome Campus, ; Hinxton, Cambridgeshire UK
                [3 ]GRID grid.15895.30, ISNI 0000 0001 0738 8966, WHO Collaborating Centre for Gonorrhoea and other STIs, Swedish Reference Laboratory for STIs, Faculty of Medicine and Health, , Örebro University, ; Örebro, Sweden
                [4 ]GRID grid.1008.9, ISNI 0000 0001 2179 088X, Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, , The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, ; Melbourne, VIC Australia
                [5 ]Microbiotica Ltd, Biodata Innovation Centre, Wellcome Genome Campus, Hinxton, Cambridgeshire UK
                [6 ]GRID grid.62560.37, ISNI 0000 0004 0378 8294, Division of Infectious Diseases, , Brigham and Women’s Hospital and Harvard Medical School, ; Boston, MA USA
                Author information
                http://orcid.org/0000-0002-4326-2911
                http://orcid.org/0000-0001-6255-690X
                http://orcid.org/0000-0003-1372-1301
                http://orcid.org/0000-0003-4599-9164
                http://orcid.org/0000-0002-4162-0228
                http://orcid.org/0000-0002-0688-2521
                http://orcid.org/0000-0001-7363-6665
                http://orcid.org/0000-0001-5646-1314
                Article
                17980
                10.1038/s41467-020-17980-1
                7431566
                32807804
                25eeef00-4f3c-454f-bd23-5a5c20f60d97
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 26 December 2019
                : 24 July 2020
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000060, U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID);
                Award ID: 1 F32 AI145157-01
                Award ID: 1R01AI132606-01
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100000925, Department of Health | National Health and Medical Research Council (NHMRC);
                Award ID: GNT1123854
                Award Recipient :
                Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
                Funded by: FundRef https://doi.org/10.13039/100001341, Richard and Susan Smith Family Foundation (Smith Family Foundation);
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                microbial genetics,pathogens
                Uncategorized
                microbial genetics, pathogens

                Comments

                Comment on this article